Format

Send to

Choose Destination
PLoS One. 2009;4(3):e4830. doi: 10.1371/journal.pone.0004830. Epub 2009 Mar 13.

Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.

Author information

1
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

Abstract

BACKGROUND:

Promoter and 5' end methylation regulation of tumour suppressor genes is a common feature of many cancers. Such occurrences often lead to the silencing of these key genes and thus they may contribute to the development of cancer, including prostate cancer.

METHODOLOGY/PRINCIPAL FINDINGS:

In order to identify methylation changes in prostate cancer, we performed a genome-wide analysis of DNA methylation using Agilent human CpG island arrays. Using computational and gene-specific validation approaches we have identified a large number of potential epigenetic biomarkers of prostate cancer. Further validation of candidate genes on a separate cohort of low and high grade prostate cancers by quantitative MethyLight analysis has allowed us to confirm DNA hypermethylation of HOXD3 and BMP7, two genes that may play a role in the development of high grade tumours. We also show that promoter hypermethylation is responsible for downregulated expression of these genes in the DU-145 PCa cell line.

CONCLUSIONS/SIGNIFICANCE:

This study identifies novel epigenetic biomarkers of prostate cancer and prostate cancer progression, and provides a global assessment of DNA methylation in prostate cancer.

PMID:
19283074
PMCID:
PMC2653233
DOI:
10.1371/journal.pone.0004830
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center